Level of Maternal Antibody Required to Protect Neonates against Early-Onset Disease Caused by Group B Streptococcus Type Ia: A Multicenter, Seroepidemiology Study
Because of the difficulty of conducting efficacy trials of vaccines against group B streptococcus (GBS), the licensure of these vaccines may have to rely on studies that measure vaccine-induced antibody levels that correlate with protection. This study estimates the level of maternal antibody requir...
Saved in:
| Published in | The Journal of infectious diseases Vol. 184; no. 8; pp. 1022 - 1028 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Chicago, IL
The University of Chicago Press
15.10.2001
University of Chicago Press |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0022-1899 1537-6613 |
| DOI | 10.1086/323350 |
Cover
| Abstract | Because of the difficulty of conducting efficacy trials of vaccines against group B streptococcus (GBS), the licensure of these vaccines may have to rely on studies that measure vaccine-induced antibody levels that correlate with protection. This study estimates the level of maternal antibody required to protect neonates against early-onset disease (EOD) caused by GBS type Ia. Levels of maternal serum IgG GBS Ia antibodies, measured by ELISAs in 45 case patients (neonates with EOD caused by GBS Ia) and in 319 control subjects (neonates colonized by GBS Ia but without EOD) born at ⩾34 weeks gestation were compared. The probability of developing EOD declined with increasing maternal levels of IgG GBS Ia antibody (P=.03). Neonates whose mothers had levels of IgG GBS Ia antibody ⩾5 μg/mL had an 88% lower risk (95% confidence interval, 7%–98%) of developing type-specific EOD, compared with those whose mothers had levels <0.5 μg/mL. A vaccine that induces IgG GBS Ia antibody levels ⩾5 μg/mL in mothers can be predicted to confer a high degree of type-specific immunity to EOD to their infants |
|---|---|
| AbstractList | Because of the difficulty of conducting efficacy trials of vaccines against group B streptococcus (GBS), the licensure of these vaccines may have to rely on studies that measure vaccine-induced antibody levels that correlate with protection. This study estimates the level of maternal antibody required to protect neonates against early-onset disease (EOD) caused by GBS type Ia. Levels of maternal serum IgG GBS Ia antibodies, measured by ELISAs in 45 case patients (neonates with EOD caused by GBS Ia) and in 319 control subjects (neonates colonized by GBS Ia but without EOD) born at greater than or equal to 34 weeks gestation were compared. The probability of developing EOD declined with increasing maternal levels of IgG GBS Ia antibody (P = .03). Neonates whose mothers had levels of IgG GBS Ia antibody greater than or equal to 5 mu g/mL had an 88% lower risk (95% confidence interval, 7%-98%) of developing type-specific EOD, compared with those whose mothers had levels <0.5 mu g/mL. A vaccine that induces IgG GBS Ia antibody levels greater than or equal to 5 mu g/mL in mothers can be predicted to confer a high degree of type-specific immunity to EOD to their infants. Because of the difficulty of conducting efficacy trials of vaccines against group B streptococcus (GBS), the licensure of these vaccines may have to rely on studies that measure vaccine-induced antibody levels that correlate with protection. This study estimates the level of maternal antibody required to protect neonates against early-onset disease (EOD) caused by GBS type Ia. Levels of maternal serum IgG GBS Ia antibodies, measured by ELISAs in 45 case patients (neonates with EOD caused by GBS Ia) and in 319 control subjects (neonates colonized by GBS Ia but without EOD) born at ⩾34 weeks gestation were compared. The probability of developing EOD declined with increasing maternal levels of IgG GBS Ia antibody (P=.03). Neonates whose mothers had levels of IgG GBS Ia antibody ⩾5 μg/mL had an 88% lower risk (95% confidence interval, 7%-98%) of developing type-specific EOD, compared with those whose mothers had levels <0.5 μg/mL. A vaccine that induces IgG GBS Ia antibody levels ⩾5 μg/mL in mothers can be predicted to confer a high degree of type-specific immunity to EOD to their infants Because of the difficulty of conducting efficacy trials of vaccines against group B streptococcus (GBS), the licensure of these vaccines may have to rely on studies that measure vaccine-induced antibody levels that correlate with protection. This study estimates the level of maternal antibody required to protect neonates against early-onset disease (EOD) caused by GBS type Ia. Levels of maternal serum IgG GBS Ia antibodies, measured by ELISAs in 45 case patients (neonates with EOD caused by GBS Ia) and in 319 control subjects (neonates colonized by GBS Ia but without EOD) born at > or =34 weeks gestation were compared. The probability of developing EOD declined with increasing maternal levels of IgG GBS Ia antibody (P = .03). Neonates whose mothers had levels of IgG GBS Ia antibody > or =5 microg/mL had an 88% lower risk (95% confidence interval, 7%-98%) of developing type-specific EOD, compared with those whose mothers had levels < 0.5 microg/mL. A vaccine that induces IgG GBS Ia antibody levels > or =5 microg/mL in mothers can be predicted to confer a high degree of type-specific immunity to EOD to their infants. Because of the difficulty of conducting efficacy trials of vaccines against group B streptococcus (GBS), the licensure of these vaccines may have to rely on studies that measure vaccine-induced antibody levels that correlate with protection. This study estimates the level of maternal antibody required to protect neonates against early-onset disease (EOD) caused by GBS type Ia. Levels of maternal serum IgG GBS Ia antibodies, measured by ELISAs in 45 case patients (neonates with EOD caused by GBS Ia) and in 319 control subjects (neonates colonized by GBS Ia but without EOD) born at > or =34 weeks gestation were compared. The probability of developing EOD declined with increasing maternal levels of IgG GBS Ia antibody (P = .03). Neonates whose mothers had levels of IgG GBS Ia antibody > or =5 microg/mL had an 88% lower risk (95% confidence interval, 7%-98%) of developing type-specific EOD, compared with those whose mothers had levels < 0.5 microg/mL. A vaccine that induces IgG GBS Ia antibody levels > or =5 microg/mL in mothers can be predicted to confer a high degree of type-specific immunity to EOD to their infants.Because of the difficulty of conducting efficacy trials of vaccines against group B streptococcus (GBS), the licensure of these vaccines may have to rely on studies that measure vaccine-induced antibody levels that correlate with protection. This study estimates the level of maternal antibody required to protect neonates against early-onset disease (EOD) caused by GBS type Ia. Levels of maternal serum IgG GBS Ia antibodies, measured by ELISAs in 45 case patients (neonates with EOD caused by GBS Ia) and in 319 control subjects (neonates colonized by GBS Ia but without EOD) born at > or =34 weeks gestation were compared. The probability of developing EOD declined with increasing maternal levels of IgG GBS Ia antibody (P = .03). Neonates whose mothers had levels of IgG GBS Ia antibody > or =5 microg/mL had an 88% lower risk (95% confidence interval, 7%-98%) of developing type-specific EOD, compared with those whose mothers had levels < 0.5 microg/mL. A vaccine that induces IgG GBS Ia antibody levels > or =5 microg/mL in mothers can be predicted to confer a high degree of type-specific immunity to EOD to their infants. |
| Author | Brenner, Ruth A. Bhushan, Reva Lin, Feng-Ying C. Philips, Joseph B. Weisman, Leonard E. Fitzgerald, Geri Azimi, Parvin H. Rhoads, George G. Troendle, James Moyer, Patricia Concepcion, Nelydia F. Clark, Penny Regan, Joan Clemens, John D. Frasch, Carl E. Gray, Barry M. |
| Author_xml | – sequence: 1 givenname: Feng-Ying C. surname: Lin fullname: Lin, Feng-Ying C. email: Link@exchange.nih.gov organization: National Institute of Child Health and Human Development, National Institutes of Health – sequence: 2 givenname: Joseph B. surname: Philips fullname: Philips, Joseph B. organization: Department of Pediatrics, University of Alabama at Birmingham – sequence: 3 givenname: Parvin H. surname: Azimi fullname: Azimi, Parvin H. organization: Children's Hospital Medical Center of Northern California, Oakland – sequence: 4 givenname: Leonard E. surname: Weisman fullname: Weisman, Leonard E. organization: Baylor College of Medicine, Houston, Texas – sequence: 5 givenname: Penny surname: Clark fullname: Clark, Penny organization: Department of Obstetrics and Gynecology, University of Florida, Gainesville – sequence: 6 givenname: George G. surname: Rhoads fullname: Rhoads, George G. organization: Department of Environmental and Community Medicine, University of Medicine and Dentistry of New Jersey, Piscataway – sequence: 7 givenname: Joan surname: Regan fullname: Regan, Joan organization: Columbia University Health Sciences, New York, New York – sequence: 8 givenname: Nelydia F. surname: Concepcion fullname: Concepcion, Nelydia F. organization: Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda – sequence: 9 givenname: Carl E. surname: Frasch fullname: Frasch, Carl E. organization: Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda – sequence: 10 givenname: James surname: Troendle fullname: Troendle, James organization: National Institute of Child Health and Human Development, National Institutes of Health – sequence: 11 givenname: Ruth A. surname: Brenner fullname: Brenner, Ruth A. organization: National Institute of Child Health and Human Development, National Institutes of Health – sequence: 12 givenname: Barry M. surname: Gray fullname: Gray, Barry M. organization: Department of Pediatrics, University of Alabama at Birmingham – sequence: 13 givenname: Reva surname: Bhushan fullname: Bhushan, Reva organization: Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda – sequence: 14 givenname: Geri surname: Fitzgerald fullname: Fitzgerald, Geri organization: Westat, Rockville, Maryland – sequence: 15 givenname: Patricia surname: Moyer fullname: Moyer, Patricia organization: National Institute of Child Health and Human Development, National Institutes of Health – sequence: 16 givenname: John D. surname: Clemens fullname: Clemens, John D. organization: National Institute of Child Health and Human Development, National Institutes of Health |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14156720$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11574917$$D View this record in MEDLINE/PubMed |
| BookMark | eNqF0c9u1DAQBnALFdE_wCMgc4BTA3Zsxwm33W1pi7btihYJcYm89qQyzdqp7SDyOjwpWe3CSiDEaS6_-Uaa7xDtOe8AoeeUvKGkLN6ynDFBHqEDKpjMioKyPXRASJ5ntKyqfXQY41dCCGeFfIL2KRWSV1QeoB9z-AYt9g2-VAmCUy2euGSX3gz4Izz0NoDByeNF8Al0wlfg3QgjVnfKupjwqQrtkF27CAmf2AgqAp6pPo5rywGfBd93eIpvUoAuee217iO-HTrAF-odnuDLvk1WgxtvH-MbCB46a2BlfevvhnGtN8NT9LhRbYRn23mEPr0_vZ2dZ_Prs4vZZJ5pzvKUKWEME6bihrC8qowmxpScjy8gmmojgSq-npw3lWpYQQrR5LwSqlwKLknFjtDrTW4X_EMPMdUrGzW0rXLg-1hLmhNS8vy_kJa54ISu4Yst7JcrMHUX7EqFof71_hG82gIVtWqboJy2cec4FYXMye6iDj7GAM2OkHrdf73pf4THf0Btk0rWuxSUbf_mLzd8bOnfkdnG2Jjg-2-lwn1dSCZFff75S30yXUxLubiqP7CfWiTJHw |
| CODEN | JIDIAQ |
| CitedBy_id | crossref_primary_10_3389_fmicb_2018_00437 crossref_primary_10_3389_fped_2020_00569 crossref_primary_10_1016_S1201_9712_03_90006_3 crossref_primary_10_1371_journal_pone_0160249 crossref_primary_10_1586_erv_11_61 crossref_primary_10_1016_j_clp_2010_02_002 crossref_primary_10_1097_INF_0b013e31821dc76f crossref_primary_10_1097_QCO_0000000000000266 crossref_primary_10_1016_j_chom_2008_05_004 crossref_primary_10_1586_14760584_2014_953939 crossref_primary_10_1590_S0041_87812003000500006 crossref_primary_10_1080_21645515_2024_2330138 crossref_primary_10_1186_s12879_015_1266_4 crossref_primary_10_1016_j_vaccine_2015_08_047 crossref_primary_10_3389_fimmu_2018_02674 crossref_primary_10_1203_PDR_0b013e31816fdbff crossref_primary_10_1016_S2666_5247_24_00038_7 crossref_primary_10_3389_fmicb_2022_820365 crossref_primary_10_1016_S0246_0335_04_22242_6 crossref_primary_10_1016_j_vaccine_2015_10_019 crossref_primary_10_1016_j_vaccine_2016_12_029 crossref_primary_10_1177_2051013615579869 crossref_primary_10_1093_cid_ciaa1873 crossref_primary_10_1097_QCO_0b013e3281a7ec98 crossref_primary_10_1093_cid_ciy1069 crossref_primary_10_1080_21645515_2022_2037350 crossref_primary_10_1016_S1473_3099_15_00484_3 crossref_primary_10_1016_j_vaccine_2019_04_039 crossref_primary_10_1016_S1473_3099_17_30232_3 crossref_primary_10_1111_sji_12258 crossref_primary_10_1038_jp_2009_95 crossref_primary_10_1128_JCM_02105_07 crossref_primary_10_1097_00063198_200305000_00012 crossref_primary_10_1111_j_1440_1754_2004_00507_x crossref_primary_10_1016_j_vaccine_2012_11_046 crossref_primary_10_1016_j_vaccine_2014_01_062 crossref_primary_10_1016_S1283_081X_05_43395_0 crossref_primary_10_1093_cid_ciw377 crossref_primary_10_1016_S1473_3099_18_30659_5 crossref_primary_10_1155_2015_167089 crossref_primary_10_1093_cid_cix666 crossref_primary_10_1128_IAI_00837_07 crossref_primary_10_3109_14767058_2010_482605 crossref_primary_10_1016_j_vaccine_2013_01_009 crossref_primary_10_1080_21645515_2018_1493326 crossref_primary_10_1093_infdis_jit549 crossref_primary_10_1016_j_vaccine_2014_06_003 crossref_primary_10_1016_j_jnn_2015_01_001 crossref_primary_10_1016_j_vaccine_2020_08_056 crossref_primary_10_1080_14760584_2017_1237875 crossref_primary_10_1093_infdis_jiz062 crossref_primary_10_2147_IDR_S291511 crossref_primary_10_1093_jpids_piw080 crossref_primary_10_3390_pathogens12020229 crossref_primary_10_1086_426820 crossref_primary_10_1111_j_1469_0691_2004_00931_x crossref_primary_10_1038_jp_2016_201 crossref_primary_10_1016_j_cellimm_2024_104807 crossref_primary_10_1097_00001432_200206000_00015 crossref_primary_10_1099_mic_0_050013_0 crossref_primary_10_1093_cid_ciz737 crossref_primary_10_1016_j_jinf_2018_01_006 crossref_primary_10_1586_14760584_3_4_371 crossref_primary_10_2147_IDR_S203454 crossref_primary_10_1093_ije_dyaf002 crossref_primary_10_1016_j_vaccine_2023_11_056 crossref_primary_10_1080_21645515_2024_2311480 crossref_primary_10_1080_21645515_2019_1688036 crossref_primary_10_1097_00006250_200209000_00022 crossref_primary_10_1016_j_vaccine_2012_04_048 crossref_primary_10_1097_01_inf_0000239322_58890_94 crossref_primary_10_1038_s41541_023_00667_1 crossref_primary_10_1016_j_vaccine_2016_09_015 crossref_primary_10_1016_j_vaccine_2025_127016 crossref_primary_10_1016_S1473_3099_16_00152_3 crossref_primary_10_1016_j_vaccine_2021_10_022 crossref_primary_10_3310_hta23670 crossref_primary_10_1016_j_vaccine_2013_02_029 crossref_primary_10_5005_jp_journals_11002_0022 crossref_primary_10_1016_j_emcgo_2004_08_001 crossref_primary_10_1586_14760584_4_2_207 crossref_primary_10_1038_s41417_021_00308_6 crossref_primary_10_1128_IAI_06232_11 crossref_primary_10_1016_j_vaccine_2017_02_025 crossref_primary_10_1080_14767058_2016_1265932 crossref_primary_10_12688_f1000research_9363_1 crossref_primary_10_1016_j_vaccine_2016_02_044 crossref_primary_10_1016_j_vaccine_2017_04_013 |
| ContentType | Journal Article |
| Copyright | 2001 by the Infectious Diseases Society of America 2001 2002 INIST-CNRS |
| Copyright_xml | – notice: 2001 by the Infectious Diseases Society of America 2001 – notice: 2002 INIST-CNRS |
| DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QL C1K 7X8 |
| DOI | 10.1086/323350 |
| DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | Bacteriology Abstracts (Microbiology B) MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1537-6613 |
| EndPage | 1028 |
| ExternalDocumentID | 11574917 14156720 10_1086_323350 10.1086/323350 ark_67375_HXZ_DBPB87PN_J |
| Genre | Multicenter Study Research Support, U.S. Gov't, P.H.S Journal Article |
| GrantInformation_xml | – fundername: NICHD NIH HHS grantid: HD-43218 – fundername: NICHD NIH HHS grantid: HD-43220 – fundername: NICHD NIH HHS grantid: HD-43215 – fundername: NICHD NIH HHS grantid: HD-43217 – fundername: NICHD NIH HHS grantid: HD-53233 – fundername: NICHD NIH HHS grantid: HD-43214 – fundername: NICHD NIH HHS grantid: HD-43219 |
| GroupedDBID | --- -DZ -~X ..I .2P .55 .GJ .I3 .XZ .ZR 08P 0R~ 123 1TH 29K 2AX 2WC 36B 3O- 4.4 48X 53G 5GY 5RE 5VS 5WD 70D 85S AABZA AACGO AACZT AAHBH AAHTB AAJKP AAMVS AANCE AAOGV AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWTL ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPEJ ABPLY ABPPZ ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ABZBJ ACGFO ACGFS ACGOD ACHIC ACPRK ACUFI ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADQXQ ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFHKK AFIYH AFOFC AFXAL AFYAG AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AI. AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQVQM ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BR6 BSCLL BTRTY BVRKM C45 CDBKE CS3 CZ4 D-I DAKXR DCCCD DIK DILTD DU5 D~K EBS ECGQY EE~ EJD EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H5~ HAR HQ3 HTVGU HW0 HZ~ IH2 IOX IPSME J21 J5H JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B LSO LU7 MHKGH MJL ML0 MVM N4W N9A NEJ NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TR2 VH1 W2D W8F WH7 X7H X7M Y6R YAYTL YKOAZ YXANX ZGI ZXP ~91 AASNB ADACV ADJQC ADRIX AFXEN DOOOF ESX JSODD M49 AAYXX AGORE CITATION 1KJ 41~ AAFWJ AAJQQ AAPGJ AAWDT ABDPE ABSMQ ACFRR ACPQN ACUTJ ACVCV ACZBC ADMTO AEKPW AFFQV AFQQW AFSHK AGKRT AGMDO AHGBF AJDVS APJGH AQDSO AQKUS AVNTJ BZKNY EIHJH H13 IQODW MBLQV OBFPC O~Y P0- TMA ZE2 CGR CUY CVF ECM EIF NPM VXZ YIF 7QL C1K 7X8 |
| ID | FETCH-LOGICAL-c432t-a5dd35d94d03299dc0dd8440220c1cd7e1a41cd744f9af36065f2495a8b547093 |
| ISSN | 0022-1899 |
| IngestDate | Fri Jul 11 15:39:48 EDT 2025 Fri Jul 11 12:24:11 EDT 2025 Wed Feb 19 01:25:23 EST 2025 Mon Jul 21 09:17:40 EDT 2025 Tue Jul 01 03:23:08 EDT 2025 Thu Apr 24 23:01:27 EDT 2025 Wed Sep 11 04:50:43 EDT 2024 Sat Sep 20 11:02:49 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Human Antibody Multicenter study IgG Infant Vaccine Infection Streptococcaceae Specificity Streptococcal infection Streptococcus B Streptococcus A Bacteriosis Bacteria Micrococcales Serum ELISA assay |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c432t-a5dd35d94d03299dc0dd8440220c1cd7e1a41cd744f9af36065f2495a8b547093 |
| Notes | istex:1CB28224890CBCF3C7C1B92441BA213956E6F77E ark:/67375/HXZ-DBPB87PN-J Present affiliations: Regional Pediatric Service, Spartanberg, South Carolina (B.M.G.); Iowa State University, Ames (R.B.); International Vaccine Institute, Seoul, South Korea (J.D.C) ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
| OpenAccessLink | https://academic.oup.com/jid/article-pdf/184/8/1022/18003458/184-8-1022.pdf |
| PMID | 11574917 |
| PQID | 18254012 |
| PQPubID | 23462 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_71200842 proquest_miscellaneous_18254012 pubmed_primary_11574917 pascalfrancis_primary_14156720 crossref_primary_10_1086_323350 crossref_citationtrail_10_1086_323350 oup_primary_10_1086_323350 istex_primary_ark_67375_HXZ_DBPB87PN_J |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2001-10-15 |
| PublicationDateYYYYMMDD | 2001-10-15 |
| PublicationDate_xml | – month: 10 year: 2001 text: 2001-10-15 day: 15 |
| PublicationDecade | 2000 |
| PublicationPlace | Chicago, IL |
| PublicationPlace_xml | – name: Chicago, IL – name: United States |
| PublicationTitle | The Journal of infectious diseases |
| PublicationTitleAbbrev | The Journal of Infectious Diseases |
| PublicationTitleAlternate | The Journal of Infectious Diseases |
| PublicationYear | 2001 |
| Publisher | The University of Chicago Press University of Chicago Press |
| Publisher_xml | – name: The University of Chicago Press – name: University of Chicago Press |
| SSID | ssj0004367 |
| Score | 2.054151 |
| Snippet | Because of the difficulty of conducting efficacy trials of vaccines against group B streptococcus (GBS), the licensure of these vaccines may have to rely on... |
| SourceID | proquest pubmed pascalfrancis crossref oup istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1022 |
| SubjectTerms | Age of Onset Antibodies, Bacterial - blood Bacterial diseases Biological and medical sciences Female Fetal Blood - immunology Human bacterial diseases Human viral diseases Humans Immunity, Maternally-Acquired Immunoglobulin G - blood Infant, Newborn Infectious diseases Medical sciences Predictive Value of Tests Pregnancy Pregnancy Complications - immunology Staphylococcal infections, streptococcal infections, pneumococcal infections Streptococcal Infections - immunology Streptococcal Infections - prevention & control Streptococcus Streptococcus agalactiae - immunology Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids |
| Title | Level of Maternal Antibody Required to Protect Neonates against Early-Onset Disease Caused by Group B Streptococcus Type Ia: A Multicenter, Seroepidemiology Study |
| URI | https://api.istex.fr/ark:/67375/HXZ-DBPB87PN-J/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/11574917 https://www.proquest.com/docview/18254012 https://www.proquest.com/docview/71200842 |
| Volume | 184 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1537-6613 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004367 issn: 0022-1899 databaseCode: KQ8 dateStart: 19970401 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1537-6613 dateEnd: 20241001 omitProxy: true ssIdentifier: ssj0004367 issn: 0022-1899 databaseCode: DIK dateStart: 19970101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1537-6613 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004367 issn: 0022-1899 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLXGJhASQjC-NmD4AXgJqZrYjlPe1jHopjH2sImOl8iJnakC2qpNJbqfwz_kH3CvnbTJ2Ph6SarEtaLcY-fY99x7CXkeZaEKhen4sRDa5yLkfipM288N4ClOcx1qq7Y4jHonfL8v-isrP2qqpVmRtrLzS-NK_seqcA3silGy_2DZRadwAX6DfeEIFobjX9n4ABU_TsTicjljLoBBOtJIrFHiC2yyQJmFzcUAExpulZupp87UAGihZ7Mb-x-GU1NgGk701Hg7ajZ1rNTtU3Wt43pcjGDmzGZTDxeu3p5yEe02fBf1nWX5LjMZmWXJ2blVKTb8xstItDJZhZOCQb-lp2hB8Q9ccgN432f-qRUntOoejIYDw-su7m2fD74OHDWGSXDo9RZ3PprBtIq0wBcx0d5uq7HpYVV3LuyzVYXN_Vm4UgUrBLGrwdQy1RwvfaAlrPkR4DW0x7UpHZfENXqAhOzST0_besJYyJjLpHshjffFJtfIWiijCItuvOsvVUmcRbJKcI_PXSuH5f7X4E9rOBV8q2Izb43VFAZ27iqyXL1kstTp-A65XdqbbjsA3yUrZrhOrrsqqPN1cuN9qe-4R75bRNNRTitE0wrRtEI0LUa0RDStEE1LRNMaommJaOoQTdM5tYimXdpANEVE0z31mm7TGp5f0YtophbN98nJ293jnZ5fVhHxM87CwldCayZ0h-s2A-6ls7bWMecYYZ4FmZYmUBzPnOcdlTNY0IscC7KrOBVctjvsAVkdjobmEaEMehFAidNQMW7COM5NaDq5jCOuTCTZBnlR2SbJyhT7WOnlS2KlHnGUOBtukGeLdmOXVOaXFi-taRe31eQzSjClSHr9T8mb7lE3lkeHyf4G2YQ3d2UvWw1ILJvhto0M8UEqjCTwWUFfoRoaGPRJgDtHQF6vbiEDlE5xaPHQgWvZeyAk7wRy83fP9pjcXA7sJ2S1mMzMU-D3RbplR8RPBw76zA |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Level+of+Maternal+Antibody+Required+to+Protect+Neonates+against+Early-Onset+Disease+Caused+by+Group+B+Streptococcus+Type+Ia%3A+A+Multicenter%2C+Seroepidemiology+Study&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Lin%2C+Feng-Ying+C.&rft.au=Philips%2C+Joseph+B.&rft.au=Azimi%2C+Parvin+H.&rft.au=Weisman%2C+Leonard+E.&rft.date=2001-10-15&rft.pub=The+University+of+Chicago+Press&rft.issn=0022-1899&rft.eissn=1537-6613&rft.volume=184&rft.issue=8&rft.spage=1022&rft.epage=1028&rft_id=info:doi/10.1086%2F323350&rft.externalDocID=10.1086%2F323350 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon |